Bringing a new drug—or a new formula—to market is an exciting time for pharmaceutical companies, but getting the formulation correct can be challenging. Low aqueous solubility is a top concern encountered with formulation development of new chemical entities (NCEs). Improper drug solubility can lead to suboptimal drug delivery and absorption, resulting in ineffective drug efficacy and side effects. That’s why solubility of drugs must be evaluated in the early stages of drug discovery.
Solubility is the ability for a drug to be dissolved in an aqueous medium. Drug solubility is defined as the maximum concentration of a substance that can be completely dissolved in a given solvent at a certain temperature and pressure level.
Solubility of drugs is measured by the amount of solvent needed to dissolve one gram of the drug at a specific temperature. For example, a drug that is very soluble needs less than one part solvent to dissolve one gram of the drug. How soluble a drug is varies widely—a drug that is considered soluble needs 10-30 parts, one that is slightly soluble needs 100-1,000 parts and one that is practically insoluble or insoluble needs more than 10,000 parts. How soluble a drug is depends on the solvent, as well as temperature and pressure.
Oral dosage is a common drug delivery route thanks to high patient adherence, cost effectiveness, ease of taking the drug, flexibility in design of the dosage and lower sterility constraints. A hurdle, however, is designing and formulating a drug with aqueous solubility, drug permeability, dissolution rate, first-pass metabolism, pre-systemic metabolism and susceptibility to efflux mechanisms. Poor solubility and low permeability are the most frequent barriers of oral bioavailability of drugs.
Drug solubility has one of the highest impacts on the desired concentration of a drug in systemic circulation, and therefore whether or not the drug will have the desired impact or pharmacological response in patients. Drugs that have poor aqueous solubility have a slower drug absorption rate, which can lead to inadequate and variable bioavailability, and render the drug ineffective.
Drug absorption through an oral dosage relies on disintegration into small molecules which can be dissolved and pass into the aqueous channels for GIT absorption into the bloodstream. Some factors that impact drug absorption include surface area, presence of food for drug binding and blood supply.
In order for a drug to be absorbed, it needs to be lipid soluble to pass through membranes, unless it has an active transport system or the molecules are so small that they can pass through the aqueous channels in the membrane. Drugs that are not soluble enough to move from the stomach and intestines into the bloodstream, may result in low systemic bioavailability and therefore, suboptimal drug performance.
Solubility plays a critical role in drug effectiveness. Without it, a drug substance cannot be absorbed, leading to low bioavailability. Poor solubility of drugs also leads to other issues, such as challenges with metabolism or permeability, interactions with other drugs or the need to extend drug release.
While scrapping your drug and developing completely new drugs is one option, introducing new technology or formulations reduces risk and cost and helps adhere to drug development timelines.
That’s where nanotization comes in.
You may be able to improve dissolution rates of poorly soluble drugs by producing drug nanoparticles with a mean particle size below 1 μm. Nanoparticles are able to dissolve more quickly and can also cross a number of biological barriers, including BBB, different types of mucosa and cell membranes.
Ascendia’s technologies make the insoluble soluble through nano-technology, which is providing new options for pharmaceutical products to be developed with improved biopharmaceutical properties. Nano-technology in the pharmaceutical field encompasses many types of formulation approaches, from nanoparticles to self-emulsifying lipid systems, to dispersed amorphous systems, to nano-emulsions. Ascendia’s suite of state-of-the-art technologies for formulating poorly water-soluble compounds provide sophisticated formulation options.
Pharma contract development manufacturing companies (CDMOs) that use multiple formulation technologies to address each compound’s unique properties helps aid successful drug development, and Ascendia has three patented IP technologies that address poor solubility and bioavailability:
Ascendia Pharmaceuticals is a CDMO that specializes in the invention and development of specialty pharmaceutical products and novel formulation technologies, providing pharmaceutical companies with rapid, comprehensive and cost-effective solutions. We’re ready to hit the ground running — so contact us today!